CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of priority under 35 U.S.C. §119(e) of U.S. Serial No. 62/949,378, filed December 17, 2019, the entire contents of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] The invention involves the provision of a recombinant algal mutant organisms for the production of lipids.

INCORPORATION OF SEQUENCE LISTING

[0003] The material in the accompanying sequence listing is hereby incorporated by reference into this application. The accompanying sequence listing text file, name SGI2240_lWO_Sequence_Listing, was created on December 14, 2020, and is 129 kb. The file can be accessed using Microsoft Word on a computer that uses Windows OS.

BACKGROUND OF THE INVENTION

[0004] The production of biodiesel fuels presents great opportunities to develop environmentally sound sources of energy that can be obtained at reasonable cost. Efforts have been directed towards using algae or other microorganisms to produce hydrocarbons that can be used as biodiesel due to their high lipid content. Additional specialty chemicals can also be obtained from these organisms and for use in consumer products.

[0005] Since algae use energy from sunlight to combine water and carbon dioxide to produce biomass, achieving increased productivity offers the possibility of a carbon neutral fuel source. The development of algal strains with very high lipid productivity for the production of algal-sourced biofuels therefore presents the possibility of a significant reduction in carbon dioxide released into the atmosphere and a consequent reduction in the problem of global warming.

[0006] Strategies for increasing algal production of biofuels and other products have included modification of nutrition provided to the organisms, such as cultivating the organisms in nitrogen, phosphorus, or silicon deficient media. Other strategies have included modification of cultivation or environmental protocols, or various efforts directed towards genetic engineering of the organisms. However, wild type algal strains have not been sufficiently productive to permit an economically viable development of this resource. Higher levels of cell productivity are necessary to efficiently utilize this energy source and achieving sufficient productivity remains an important barrier.

SUMMARY OF THE INVENTION

[0007] The invention involves methods and recombinant algal mutants that have a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic enzyme, and/or a genetic modification to a nucleic acid encoding an RNA binding domain. Attenuation of either or both of these genes results in a mutant organism with increased lipid productivity. It was also discovered that one, two, three, or more genetic mutations can be accumulated or “stacked” in a particular mutant cell or organism to result in further increases in the production of lipid products. The lipid products of these mutants can be utilized as biofuels or for other specialty chemical products. In some embodiments the recombinant algal mutants that have a genetic modification in a nucleic acid sequence encoding a trehalose biosynthetic enzyme or can have a genetic modification in a nucleic acid sequence encoding an RNA binding domain. In other embodiments the algal mutants can have both of these genetic modifications. And in some embodiments, any of these algal mutants can additionally (and optionally) have a genetic mutation to a nucleic acid sequence encoding an SGI1 polypeptide. Each of these algal mutants exhibit increased lipid productivity versus a control algae.

[0008] In a first aspect the invention provides a recombinant algal cell having a genetic modification in a nucleic acid sequence encoding a trehalose biosynthesis pathway enzyme; and/or a genetic modification in a nucleic acid sequence encoding an RNA binding domain; wherein the recombinant alga exhibits increased lipid productivity versus a corresponding control algal cell. In one embodiment the genetic modification results in an attenuation of expression of the nucleic acid sequence having the genetic modification. In one embodiment the recombinant alga can has a genetic modification in the nucleic acid sequence encoding the trehalose biosynthesis pathway enzyme and a genetic modification in the nucleic acid sequence encoding the RNA binding domain. In any of the embodiments the recombinant alga can be a Chlorophyte alga and, optionally, of the Class Trebouxiophyceae.

[0009] In various embodiments the trehalose biosynthesis pathway enzyme can be any one of a trehalose-6-phosphate synthase, or a trehalose-6-phosphate phosphatase, or a trehalose-6- phosphate synthase/phosphatase. In any of the embodiments the recombinant alga can further have an attenuation of a nucleic acid sequence encoding an SGI1 polypeptide. In one embodiment the recombinant alga has a genetic modification in a nucleic acid sequence encoding a trehalose biosynthesis pathway enzyme (e.g. trehalose-6-phosphate synthase/phosphatase), and a genetic modification in a nucleic acid sequence encoding an RNA binding domain, and an attenuation of a nucleic acid sequence encoding an SGI1 polypeptide, and the recombinant alga exhibits increased lipid productivity versus a corresponding control algal cell.

[0010] In one embodiment the genetic modification to the nucleic acid sequence encoding the RNA binding domain is a functional deletion. In one embodiment the nucleic acid sequence encoding the trehalose-6-phosphate synthase/phosphatase can have a substitution mutation versus the wild type sequence. In any of the embodiments the nucleic acid sequence encoding the trehalose-6-phosphate synthase phosphatase can have at least 90% sequence identity to SEQ ID NO: 2. In any of the embodiments the nucleic acid sequence encoding the RNA binding domain can have at least 90% sequence identity to SEQ ID NO: 1.

[0011] In some embodiments the substitution mutation in the nucleic acid sequence encoding the trehalose-6-phosphate synthase phosphatase is a E723 V mutation versus the wild type sequence, and the recombinant algal cell is an alga of the genus Parachlorella. The genetic modification of the nucleic acid sequence encoding the trehalose biosynthetic enzyme and the nucleic acid sequence encoding the RNA binding domain can result in an attenuation in the expression of each of the nucleic acid sequences. In various embodiments the recombinant alga has at least 50% or at least 60% or at least 70% or at least 80% or at least 90% or at least 2x greater lipid productivity versus a control algae. And in some embodiments the recombinant alga can have (alone or in addition to greater lipid productivity) at least 50% or at least 60% or at least 70% or at least 80% or at least 90% or at least 2x greater biomass productivity versus a control algae. In some embodiments the recombinant alga has at least 5 grams per square meter per day of lipid production. The recombinant alga can also have a higher biomass productivity per unit time versus a control alga. The recombinant alga can have the stated higher biomass productivity and/or the stated higher total organic carbon production under nitrogen deficient conditions.

[0012] In various embodiments the recombinant alga can be a Chlorophyte algae of any of the genera selected from Chlorella, Parachlorella, Picochlorum, Tetraselmis, and Oocystis. [0013] In another aspect the invention provides a method of producing a composition containing lipids. The methods involve cultivating an algal organism having a genetic modification in a nucleic acid sequence encoding a trehalose biosynthetic enzyme and/or a genetic modification in a nucleic acid sequence encoding an RNA binding domain; and thereby producing a composition containing lipids. In any embodiment the algal organism can also have an attenuation in expression of a nucleic acid sequence encoding an SGI1 polypeptide. Any organism described herein can be cultivated or used in the methods. [0014] In another aspect the invention involves methods of producing a recombinant lipid- producing algal organism. The methods involve introducing a genetic modification into a nucleic acid sequence encoding a trehalose biosynthetic enzyme in an algal organism, and/or introducing a genetic modification into a nucleic acid sequence encoding an RNA binding domain in an algal organism, wherein the genetic modification(s) is/are relative to a corresponding control algal organism; to thereby produce a recombinant lipid-producing algal organism; and wherein the recombinant algal organism exhibits increased lipid productivity versus a corresponding control algal organism not having the attenuation(s). Any organism described herein can be produced in the methods.

[0015] In one embodiment the methods involve introducing a genetic modification into the nucleic acid sequence encoding the trehalose biosynthetic pathway enzyme and also introducing a genetic modification into the nucleic acid sequence encoding the RNA binding domain. The methods can also involve cultivating the recombinant algal organism to thereby produce a composition containing lipids. In one embodiment the genetic modification(s) is/are introduced by mutagenesis. In any embodiment the algal organism is a Chlorophyte alga. In various embodiments the trehalose biosynthesis pathway enzyme can be trehalose-6-phosphate synthase, a trehalose-6-phosphate phosphatase, or a trehalose-6-phosphate synthase/phosphatase. In any of the embodiments the methods can also involve introducing a genetic modification into a nucleic acid sequence encoding an SGI1 polypeptide.

[0016] In some embodiments the genetic modification(s) to any one or more of the nucleic acid sequences is a functional deletion. In one embodiment the trehalose-6-phosphate biosynthetic enzyme is synthase/phosphatase and its genetic modification is a substitution mutation versus the wild type sequence. In one embodiment the nucleic acid sequence encoding the trehalose-6-phosphate synthase phosphatase has at least 90% sequence identity to SEQ ID NO: 2. In any embodiment the nucleic acid sequence of the algal organism encoding the RNA binding domain is a functional deletion. The nucleic acid sequence encoding the RNA binding domain in the algal organism can have at least 90% sequence identity to SEQ ID NO: 1

[0017] In any of the embodiments the alga can be of the Class Trebouxiophyceae. In one embodiment the substitution mutation in the nucleic acid sequence encoding the trehalose-e- phosphate synthase phosphatase is an E723 V mutation and the recombinant algal cell is an alga of the genus Parachlorella. In any embodiment the genetic modification(s) can be an attenuation in the expression of the nucleic acid sequence(s). In various embodiments the algal organism can have at least 50% greater lipid productivity versus the corresponding control algal, or at least 75% greater lipid productivity versus the corresponding control alga. The algal organism can also have at least 5 grams per square meter per day of lipid production. The algal organism can have higher biomass productivity per unit time and/or higher biomass productivity under nitrogen deficient conditions and/or higher total organic carbon production under nitrogen deficient conditions.

[0018] In any of the embodiments the recombinant alga can be a Chlorophyte alga of a genus selected from the group consisting of: Chlorella, Parachlorella, Picochlorum, Tetraselmis, and Oocystis. In one embodiment the recombinant alga is an alga of the class Chlorellales.

[0019] In one embodiment the method further involves a step of treating the algal organism with uv radiation prior to the step of cultivating. The method can also involve harvesting a lipidic composition from the algal organism.

BRIEF DESCRIPTION OF THE DRAWINGS [0020] FIGURE 1A provides a graphical illustration of a FAME/TOC productivity plot for strains isolated from BODIPY-FACS enrichment after 2-days of nitrogen deplete conditions, showing the amount of fixed carbon that is partitioned to lipids and nitrogen-deplete lipid productivity. FIGURE IB shows aerial lipid productivity (as TOC) as the mean of the first two days in nitrogen deplete conditions.

[0021] FIGURES 2A-2C, in FIGURE 2A the Tre6P recapitulation (SGIl+Tre6P) showed increased areal FAME productivity over the SGI1-KO strain (SGI1 “knock out” only) in the early stages of nitrogen starvation. By Day 6 levels fall to the same level as the SGI1-KO strain. In FIGURE 2B, RBD repair in the SGIl+Tre6P+RBD strain resulted in increased FAME productivity for the first few days of nitrogen starvation until falling to the same levels as the SGI1-KO strain by Day 6. FIGURE 2C shows the results for semi-continuous urea batch assay under 2 days of nitrogen deplete conditions for the triple mutation strain (STR0600, i.e. SGIl+RBD+Tre6P mutations) compared to the wild-type Parachlorella sp. strain. FAME production for STR600 was 53% higher.

[0022] FIGURES 3A-3B shows late improvements in lipid productivity driven by the RBD deletion. In FIGURE 3A RBD recapitulation strain (SGIl+RBD) shows areal FAME productivity equivalent to the SGI1 mutant in the early stages of nitrogen starvation but increases to almost to the levels of the triple mutant (STR00600) levels by Day 6. In the SGIl+RBD strain, the RBD SNP was introduced into a SGIl-only strain. In FIGURE 3B, Tre6P repair in the STR0600 triple mutant showed decreased FAME productivity relative to triple mutant STR0600 early in nitrogen starvation but approaches the same level as the triple mutant by Day 5.

[0023] FIGURES 4A-4B shows assay data for RBD and Tre6P mutations stacked into an SGI1 only strain. The data represent the average and standard deviation for biological duplicate cultures, where FAME and TOC productivities are determined over the first two days under nitrogen deplete conditions. FIGURE 4A shows increased FAME productivity for the SGIl-KO/RBD/Tre6P stacked mutation strains, similar to the triple mutant STR0600. FIGURE 4B shows TOC data for the same.

[0024] FIGURES 5A-5B shows mutation repair strains versus SGIl-only as background strain. FIGURE 5A shows the STR600 triple mutant (SGIl+RBD+Tre6P) versus SGI1 repair strains 680 and 681 (which have SGI1 mutation repaired) and repair strain 682 (which has RBD mutation repaired). FAME accumulation after 2 days is reduced for the repair strains versus the triple mutant (STR0600), but still higher than the SGIl-only mutants. FIGURE 5B shows similar data with respect to TOC accumulation after 2 days.

[0025] FIGURE 6 provides a graphical illustration of a biosynthetic pathway from the conversion of glucose-6-phosphate and UDP-glucose into trehalose-6-phosphate and then trehalose.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The invention provides recombinant algal mutants that have a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic pathway enzyme, and/or a genetic modification to a nucleic acid encoding an RNA binding domain. A genetic modification to either or both of these genes as described herein results in a recombinant or mutant cell or organism with higher productivity, for example higher lipid productivity. The recombinant cells or organisms can also have a higher biomass productivity. The recombinant algal mutants can also optionally have reduced chlorophyll content and/or a reduced PSII antenna size. Any of the algal mutants described herein can also, optionally, have an attenuation of a gene encoding an SGI1 polypeptide. Thus, in some embodiments the algal mutants have 1) a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic pathway enzyme, and/or 2) a genetic modification to a nucleic acid encoding an RNA binding domain; and, additionally and optionally 3) a genetic modification in a gene encoding an SGI1 polypeptide. Any of the recombinant cells or organisms disclosed herein can be mutant photosynthetic organisms. It was discovered unexpectedly that the genetic mutations disclosed herein can be accumulated or “stacked” in a cell or organism to result in further significant increases in the production of lipid products made by the cells or organisms, which further increases can be additive, more than additive, synergistic, or exponential. The stacking can be performed by recapitulating more than one of the mutations in a wild-type or other background cell or organism. The recombinant algal cells or organisms disclosed can have one, two, three, or more than two, or more than three genetic mutations described herein, and thus can have the desirable characteristics disclosed herein.

[0027] The recombinant cells or organisms of the invention can have higher FAME and/or biomass productivity than corresponding control cells or organisms that do not have a corresponding attenuation(s) of the nucleic acid sequence encoding an RBD domain and/or a nucleic acid sequence encoding a trehalose biosynthetic pathway enzyme and, optionally with either or both, a nucleic acid sequence encoding an SGI1 polypeptide, or any combination or sub-combination of these attenuations, and that are cultivated in the same or substantially the same conditions. Biomass productivity can be measured as the rate of biomass accumulation, for example, the total organic carbon content of the respective cells or organisms, which in one embodiment can be in batch cultures. Batch culture is a culture where nutrients are not renewed or re-supplied to the medium during the time period the cells or organisms are cultured. Any of the mutant cells or organisms disclosed herein can be photosynthetic cells or organisms. Any of the recombinant cells or organisms described herein can exhibit increased lipid and/or biomass productivity under photoautotrophic conditions. Corresponding (control) cells or organisms are useful for evaluating the effect of any one or more genetic modifications. Corresponding (control) cells or organisms do not have the one or more genetic modifications being evaluated and are subjected to the same or substantially the same culturing conditions as the test cells or organisms such that a difference in the performance of the cells or organisms is based only on the genetic modification(s) being evaluated. Corresponding (control) cells or organisms can be of the same species as the test organism. They can also be the same or similar in every way except for the one or more genetic modification(s) being evaluated. In some embodiments the corresponding (control) cell or organism is a wild-type cell or organism. [0028] In one embodiment the recombinant cells or organisms are algal cells. In one embodiment the recombinant alga has a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic enzyme. In another embodiment the recombinant alga has a genetic modification to a nucleic acid sequence encoding a RNA binding domain. In another embodiment the recombinant alga can have a genetic modification to a nucleic acid encoding a trehalose biosynthetic pathway enzyme and a genetic modification to a nucleic acid sequence encoding an RNA binding domain. Additionally, and optionally any of the recombinant alga can further have a genetic modification to a nucleic acid sequence encoding an SGI1 polypeptide with the genetic modification encoding an RNA binding domain and/or a genetic modification to a nucleic acid encoding a trehalose biosynthetic pathway enzyme.

[0029] The lipid products of these mutants can be further processed into biofuels or used in the production of other specialty chemical products. The nucleic acid sequences encoding the trehalose biosynthetic pathway enzyme, or the RNA binding domain, or the SGI1 polypeptide can be any of the nucleic acid sequences described herein, hereby disclosed in all possible combinations and sub-combinations.

[0030] In some embodiments any of the recombinant cells or organisms of the invention have a reduced amount of chlorophyll b, and can have an increased chlorophyll a : chlorophyll b ratio compared to a corresponding control cell or organism. The recombinant cells or organisms can have decreased photosynthetic antenna size, for example reduced photosystem II (PSII) and/or reduced photosystem I (PSI) antenna size. In various embodiments the cross- sectional unit size of the PSII and/or PSI antenna of the recombinant cells or organisms disclosed herein can be reduced by at least 10%, at least 20%, at least 30%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60% compared to the PSII and/or PSI antenna size of a corresponding control cell or organism. The recombinant cells or organisms can have higher growth rate and/or higher biomass productivity than a corresponding control cell or organism not having the genetic modification, for example, higher biomass productivity per hour or per day or per period of 2 days or 3 days or 4 days or 5 days or 6 days. “Biomass” refers to cellular mass, whether of living or dead cells. Biomass productivity, or biomass accumulation, or growth rate, can be measured by any means accepted in the art, for example as ash free dry weight (AFDW), dry weight, wet weight, or total organic carbon (TOC) productivity. In any embodiment biomass productivity, or biomass accumulation, or the growth rate, can be measured as total organic carbon (TOC) productivity. [0031] The recombinant cells or organisms of the invention can produce a greater amount of a bioproduct per time period (e.g. per minute or per hour or per day or per period of 2 days or 3 days or 4 days or 5 days or 6 days.), for example a lipid product, FAME profile, a carbohydrate, a protein product, a polyketide, a terpenoid, a pigment, an antioxidant, a vitamin, one or more nucleotides, one or more nucleic acids, one or more amino acids, one or more carbohydrates, an alcohol, a hormone, a cytokine, a peptide, or a polymer than a corresponding (control) organism not having the genetic modification(s) and being tested and cultured under substantially the same conditions over the same period of time. The amount of product can be expressed as g/time period, mg/time period, ug/time period, or any other defined quantity per defined time period described herein. Such bioproducts can be isolated from a lysate of any of the recombinant cells or organisms of the invention. In some embodiments, the recombinant cells or organisms of the invention produce at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% more of a bioproduct than a corresponding control alga cultured under the substantially the same conditions, which can be batch, semi- continuous, or continuous culture conditions and may be nutrient replete culture conditions or may be nitrogen deplete conditions, and may be photoautotrophic conditions.

[0032] Without wanting to be bound by any particular theory it is believed that the genetic modification(s) described herein result(s) in an attenuation of expression of a nucleic acid sequence encoding the trehalose biosynthetic pathway enzyme and/or a nucleic acid sequence encoding the RNA binding domain and, optionally with either or both, a nucleic acid sequence encoding the SGI1 polypeptide. These one or more attenuations result in a significant increase in the amount of lipids produced by the cell, as demonstrated by the total FAME produced by the cell. They can also result in a significant increase in biomass productivity, as demonstrated by the organic carbon produced by the cell (as measured, for example, by total organic carbon). [0033] As used herein, "exogenous" with respect to a nucleic acid or gene indicates that the nucleic acid or gene has been introduced (e.g. "transformed") into an organism, microorganism, or cell by human intervention. Typically, such an exogenous nucleic acid is introduced into a cell or organism via a recombinant nucleic acid construct. An exogenous nucleic acid can be a sequence from one species introduced into another species, i.e., a heterologous nucleic acid. A “heterologous” nucleic acid can also be an exogenous synthetic sequence not found in the species into which it is introduced. An exogenous nucleic acid can also be a sequence that is homologous to an organism (i.e., the nucleic acid sequence occurs naturally in that species or encodes a polypeptide that occurs naturally in the host species) that has been isolated and subsequently reintroduced into cells of that organism. An exogenous nucleic acid that includes a homologous sequence can often be distinguished from the naturally-occurring sequence by the presence of non-natural sequences linked to the exogenous nucleic acid, e.g., non-native regulatory sequences flanking the homologous gene sequence in a recombinant nucleic acid construct. Alternatively, or in addition, a stably transformed exogenous nucleic acid can be detected and/or distinguished from a native gene by its juxtaposition to sequences in the genome where it has integrated. Further, a nucleic acid is considered exogenous if it has been introduced into a progenitor of the cell, organism, or strain under consideration. [0034] A “recombinant” or “engineered” nucleic acid molecule is a nucleic acid molecule that has been altered through human manipulation. As non-limiting examples, a recombinant nucleic acid molecule includes any nucleic acid molecule that: 1) has been partially or fully synthesized or modified in vitro, for example, using chemical or enzymatic techniques (e.g., by use of chemical nucleic acid synthesis, or by use of enzymes for the replication, polymerization, digestion (exonucleolytic or endonucleolytic), ligation, reverse transcription, transcription, base modification (including, e.g., methylation), integration or recombination (including homologous and site-specific recombination) of nucleic acid molecules); 2) includes conjoined nucleotide sequences that are not conjoined in Nature; 3) has been engineered using molecular biology techniques such that it lacks one or more nucleotides with respect to the naturally occurring nucleic acid molecule sequence; and/or 4) has been manipulated using molecular biology techniques such that it has one or more sequence changes or rearrangements with respect to the naturally occurring nucleic acid sequence. As non-limiting examples, a cDNA is a recombinant DNA molecule, as is any nucleic acid molecule that has been generated by in vitro polymerase reaction(s), or to which linkers have been attached, or that has been integrated into a vector, such as a cloning vector or expression vector.

[0035] When applied to organisms, the terms "transgenic" "transformed" or "recombinant" or "engineered" or "genetically engineered" refer to organisms that have been manipulated by introduction of an exogenous or recombinant nucleic acid sequence into the organism, or by genetic manipulation of native sequences (which are therefore then recombinant). In some embodiments the exogenous or recombinant nucleic acid can express a heterologous protein product. Non-limiting examples of such manipulations include gene knockouts, targeted mutations and gene replacement, gene replacement, promoter replacement, deletions or insertions, disruptions in a gene or regulatory sequence, as well as introduction of transgenes into the organism. For example, a transgenic microorganism can include an introduced exogenous regulatory sequence that enables transcription in the organism operably linked to an endogenous gene of the transgenic microorganism. Recombinant or genetically engineered organisms can also be organisms into which constructs for gene "knock down," deletion, attenuation, or disruption have been introduced to perform the indicated manipulation. Such constructs include, but are not limited to, RNAi, microRNA, shRNA, antisense, and ribozyme constructs. Also included are organisms whose genomes have been altered by the activity of meganucleases or zinc finger nucleases. A heterologous or recombinant nucleic acid molecule can be integrated into a genetically engineered/recombinant organism's genome or, in other instances, not integrated into a recombinant/genetically engineered organism's genome, or can be present on a vector or other nucleic acid construct. As used herein, "recombinant microorganism" or "recombinant host cell" includes progeny or derivatives of the recombinant microorganisms of the disclosure. Because certain modifications may occur in succeeding generations from either mutation or environmental influences, such progeny or derivatives may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0036] The term "Pfam" refers to a large collection of protein domains and protein families maintained by the Pfam Consortium and available at several sponsored world wide web sites, including: pfam.sanger.ac.uk/ (Welcome Trust, Sanger Institute); pfam.sbc.su.se (Stockholm Bioinformatics Center); pfam.janelia.org/ (Janelia Farm, Howard Hughes Medical Institute); pfam.jouy.inra.fr/ (Institut national de la Recherche Agronomique); and pfam.ccbb.re.kr. Pfam domains and families are identified using multiple sequence alignments and hidden Markov models (HMMs). Pfam-A family or domain assignments are high quality assignments generated by a curated seed alignment using representative members of a protein family and profile hidden Markov models based on the seed alignment. (Unless otherwise specified, matches of a queried protein to a Pfam domain or family are Pfam-A matches.) All identified sequences belonging to the family are then used to automatically generate a full alignment for the family (Sonnhammer (1998) Nucleic Acids Research 26, 320-322; Bateman (2000) Nucleic Acids Research 26, 263-266; Bateman (2004) Nucleic Acids Research 32, Database Issue, D138-D141; Finn (2006) Nucleic Acids Research Database Issue 34, D247-251; Finn (2010) Nucleic Acids Research Database Issue 38, D211-222). By accessing the Pfam database, for example, using any of the above-reference websites, protein sequences can be queried against the HMMs using HMMER homology search software (e.g., HMMER2, HMMER3, or a higher version, hmmer.janelia.org/). Significant matches that identify a queried protein as being in a pfam family (or as having a particular Pfam domain) are those in which the bit score is greater than or equal to the gathering threshold for the Pfam domain. Expectation values (e values) can also be used as a criterion for inclusion of a queried protein in a Pfam or for determining whether a queried protein has a particular Pfam domain, where low e values (much less than 1.0, for example less than 0.1, or less than or equal to 0.01) represent low probabilities that a match is due to chance.

[0037] The recombinant cells or organisms described herein can be generated by human intervention, for example, by classical mutagenesis or genetic engineering, or by any feasible mutagenesis method, including but not limited to UV irradiation, CRISPR/Cas9, cre/lox, gamma irradiation, or chemical mutagenesis. And screening methods can be used to identify mutants having desirable characteristics (e.g., reduced chlorophyll and increased productivity. Methods for generating mutants of photosynthetic organisms using classical mutagenesis, genetic engineering, and phenotype or genotype screening are well-known in the art.

Algal Cell or Organism

[0038] The recombinant algal cell or organism of the invention can be a mutant microalga, or a mutant photosynthetic organism, or a mutant green alga. The recombinant alga can be any eukaryotic microoalga such as, but not limited to, a Chlorophyte, an Ochrophyte, or a Charophyte alga. In some embodiments the mutant microalga can be a Chlorophyte alga of the taxonomic Class Chlorophyceace, or of the Class Chlorodendrophyceae, or the Class Prasinophyceace, or the Class Trebouxiophyceae, or the Class Eustigmatophyceae. In some embodiments, the mutant microalga can be a member of the Class Chlorophyceace, such as a species of any one or more of the genera Asteromonas, Ankistrodesmus, Carteria, Chlamydomonas, Chlorococcum, Chlorogonium, Chlorodendrales, Chloroellales, Chrysosphaera, Dunaliella, Haematococcus, Monoraphidium, Neochloris, Oedogonium, Pelagomonas, Pleurococcus, Pyrobotrys, Scenedesmus, or Volvox. In other embodiments, the mutant microalga can be a member of the Class Chlorodendrophyceae, such as a species of any one or more of the genera Prasinocladus, Scherffelia, or Tetraselmis. In further alternative embodiments, the mutant alga can be a member of the Class Prasinophyceace, optionally a species of any one or more of the genera Ostreococcus or Micromonas. Further alternatively, the mutant microalga can be a member of the Class Trebouxiophyceae, and optionally of the Order Chlorellales, and optionally a genera selected from any one or more of Botryococcus, Chlorella, Auxenochlorella, Heveochlorella, Marinichlorella, Oocystis, Parachlorella, Pseudochlorella, Tetrachlorella, Eremosphaera, Franceia, Micractinium, Nannochloris, Picochlorum, Prototheca, Stichococcus, or Viridiella, or any of all possible combinations or sub-combination of the genera. In another embodiment the recombinant alga is a Chlorophyte alga of the Class Trebouxiophyceae, the Order Chlorellales, the Family Oocystaceae, Chlorellaceae, or Eustigmatophyceae, and optionally a genera selected from one or more of Oocystis, Parachlorella, Picochlorum, Nannochloropsis, and Tetraselmis. The recombinant alga can also be from the genus Oocystis, or the genus Parachlorella, or the genus Picochlorum, or the genus Tetraselmis, or from any of all possible combinations and sub-combinations of the genera.

[0039] In various embodiments the recombinant alga of the invention can have a genetic modification to a nucleic acid encoding a trehalose biosynthetic enzyme, or an RNA binding protein, or both. Any of the recombinant alga of the invention can also, optionally, have a genetic modification to a nucleic acid encoding an SGI1 polypeptide. In one embodiment the recombinant alga of the invention has a genetic modification to a nucleic acid sequence encoding a trehalose biosynthetic enzyme, a genetic modification to a nucleic acid sequence encoding an RNA binding protein, and a genetic modification to a nucleic acid encoding an SGI1 polypeptide. In one embodiment each of these genetic modifications is to a native or endogenous sequence of the cell or organism.

[0040] A “genetic modification” can denote any one or more of a deletion, a mutation, a disruption, an insertion, an inactivation, an attenuation, a rearrangement, one or more point mutations, a frameshift mutation, an inversion, a “knock out”, a “knock in”, that results in a physical change to the modified gene, and that reduces or eliminates expression of the one or more gene products. The genetic modification (e.g. to a gene or nucleic acid sequence encoding a trehalose biosynthetic pathway enzyme or RBD domain, or SGI1 polypeptide) can occur in any sequence that affects expression of the gene or the nature or quantity of its product, for example to the coding or non-coding sequence, regulatory sequence, promoter, terminator, exon, intron, 3’ or 5’ UTR. The genetic modification can be to the host cell’s native genome. In some embodiments, for example, a recombinant cell or organism having attenuated expression of a gene as disclosed herein can have one or more mutations, which can be one or more nucleobase changes and/or one or more nucleobase deletions and/or one or more nucleobase insertions, into the region of a gene 5' of the transcriptional start site, such as, in non-limiting examples, within about 2 kb, within about 1.5 kb, within about 1 kb, or within about 0.5 kb of the known or putative transcriptional start site, or within about 3 kb, within about 2.5 kb, within about 2kb, within about 1.5 kb, within about 1 kb, or within about 0.5 kb of the translational start site.

[0041] In one embodiment the genetic modification(s) can be an attenuation (but the genetic modification(s) can also be a deletion or a disruption). An “attenuation” refers to a nucleic acid sequence or gene whose function, activity, or expression is reduced compared to the amount of function, activity, or expression in a corresponding (control) organism not having the genetic modification being examined, where the cell is cultivated under the same or substantially the same conditions, i.e. the diminished function, activity, or expression is due to the genetic modification. In various embodiments an attenuated nucleic acid sequence or gene produces less than 70% or less than 50% or less than 30% or less than 20% or less than 10% or less than 5% or less than 1% of its function, activity, or expression than in a corresponding cell not having the genetic modification at issue under the same or substantially the same culturing conditions. The terms deletion cassette and disruption cassette are used interchangeably. Substantially the same conditions can be the same conditions or slightly different conditions where the change does not materially affect the function, activity, or expression of the nucleic acid sequence modified.

[0042] In various embodiments the genetic modification can be a deletion or a disruption. An unmodified nucleic acid sequence present naturally in the organism denotes a natural, endogenous, or wild type sequence. In a deletion at least part of the nucleic acid sequence is deleted, but a deletion can also be accomplished by disrupting a gene (e.g. a “knock out” mutation), or through, for example, the insertion (insertional mutation) of another sequence (e.g. a selection marker), or a combination of deletion and insertion, but a deletion can also be performed by other genetic modifications known to those of ordinary skill that result in the gene not being functionally expressed. A “disruption” of a gene is a functional deletion by insertion or deletion of a nucleotide sequence into or from the coding, non-coding, or regulatory portion of a gene with resulting partial or complete loss of function, activity, or expression of the gene. Functional expression refers to the expression of a functional product or activity of a nucleic acid sequence; when the expressed product of a nucleic acid is a polypeptide a functional polypeptide has at least some of the normal activity of the encoded polypeptide. For a nucleic acid a functional activity is at least some of the normal activity of the nucleic acid. A functional deletion or disruption removes at least so much of the expression or activity of a nucleic acid sequence that the product or activity of the nucleic acid sequence has no significant effect on the cell or organism compared to the natural or normal level of expression, i.e. the cell performs the same as a “knock out” deletion or disruption (e.g. with regard to lipid productivity or biomass productivity). When the nucleic acid sequence encodes a polypeptide, the encoded polypeptide will not be expressed in an amount that makes a significant difference in the cell or organism compared to expression in the unmodified cell or organism. When the nucleic acid sequence has an activity other than encoding a polypeptide the activity is not sufficient to display a significant effect compared to activity in the unmodified cell or organism. In some embodiments the functional deletion can remove all expression or activity of the nucleic acid sequence. In some embodiments the functional deletion is a knockout deletion. Thus, deletions, functional deletions, and disruptions can also be attenuations.

[0043] The recombinant cells or organisms of the invention can have a reduced functional absorption cross section of PSII or reduced PSII antenna size. For example, the cross-sectional unit size of the PSII antenna can be reduced by at least about 10%, at least 20%, at least 30%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least about 70%, or at least about 80% compared to the PSII antenna size of the corresponding (control) cell or organism. The recombinant cells or organisms of the invention can additionally have a reduced functional absorption cross section of PSI or reduced PSI antenna size. For example, the cross-sectional unit size of the PSI antenna can be reduced by at least 10%, at least 20%, at least 30%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60% compared to the PSI antenna size of a control photosynthetic organism.

[0044] In various embodiments, a mutant photosynthetic organism as provided herein can have increased Fv/Fm with respect to a corresponding control photosynthetic organism. For example, the mutant photosynthetic organism may have Fv/Fm increased by at least 5%, at least 10%, at least 12%, at least 15%, at least 20%, at least 30%, at least 40% or at least 50% compared to a corresponding (control) photosynthetic organism. In various embodiments the Fv/Fm can be increased by between about 5% and about 50%, or between about 5% and 30%, or between 5% and 20% with respect to a control photosynthetic organism.

[0045] Further, a mutant photosynthetic organism as provided herein can have an increased rate of electron transport on the acceptor side of photosystem II with respect to a control or wild type cell . The rate can be at least about 20%, 30%, 40%, 50%, 60%, 80%, or 100% higher compared to a corresponding control or wild type organism. In addition, mutant photosynthetic cells or organisms of the invention can have a rate of carbon fixation (Pmax (C)) in a recombinant cell or organism as provided herein can be elevated with respect to a control organism. For example, Pmax (14C ) can be increased by at least about 20%, 30%, 40%, 50%, 60%, 80%, or 100% compared to a corresponding control or wild type organism.

[0046] In some embodiments, the recombinant cells or organisms of the invention have decreased PSI and/or PSII antenna size and can optionally also have a higher amount of a ribulose bisphosphate carboxylase activase (Rubisco activase or "RA") than a corresponding (control) or wild type organism, for example, at least 1.2, 1.4, 1.6, 1.8, 2, 2.2, or 2.5 fold the amount of RA as a control organism. In some embodiments, the mutants demonstrate reduced expression of 6, 8, 10, 12, or 14 LHCP genes and increased expression of an RA gene, such as an RA-a or RA-P gene. Thus, the recombinant cells or organisms of the invention can be mutant photosynthetic organisms having reduced chlorophyll and reduced PSII antenna size where the mutants have a higher amount of Rubisco activase than control photosynthetic organisms.

[0047] The LHC super-gene family encodes the light-harvesting chlorophyll a/b-binding (LHC) proteins that constitute the antenna system of the photosynthetic apparatus. A recombinant algal mutant of the invention can also have a reduced expression of LHC genes. Thus, in some embodiments the recombinant cells or organisms of the invention have at least 6, at least 8, at least 10, or at least 12 LHC genes that are attenuated or downregulated with respect to their expression level in a corresponding (control) cell or organism. In various embodiments the reduction in expression of the LHC genes can be a reduction of at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70% in the level of LHC transcripts.

Trehalose biosynthetic pathway enzymes

[0048] The biosynthesis of trehalose is an important process and several biosynthesis pathways for the provision of trehalose have developed. The most common biosynthesis pathways involve trehalose biosynthetic pathway enzymes, which include: 1) trehalose-e- phosphate synthase (T6PS), which converts glucose-6-phosphate and UDP-glucose into trehalose-6-phosphate (T6P); 2) trehalose-6-phosphate phosphatase (T6PP), which dephosphorylates T6P into trehalose; 3) trehalase, which converts trehalose into glucose; 4) trehalose phosphate hydrolase, which converts T6P into glucose and UDPG + glucose-e- phosphate; and 5) trehalose-6-phosphate synthase/phosphatase (T6PS/P), which has both the synthase and phosphatase activity of 1) and 2) above in the same enzyme molecule.

[0049] The recombinant alga of the invention can have a genetic modification to a gene or nucleic acid sequence encoding any one or more of the trehalose biosynthetic pathway enzymes or any combination of them, which are hereby disclosed in all possible combinations and sub combinations as if set forth fully herein. In one embodiment the genetic modification is to one or more gene(s) or nucleic acid sequence(s) encoding a trehalose-6-phosphate synthase (T6PS). In another embodiment the genetic modification is to one or more nucleic acid sequence(s) or gene(s) encoding a trehalose-6-phosphate phosphatase (T6PP). In another embodiment the genetic modification is to one or more nucleic acid sequence(s) or gene(s) encoding a trehalose- e-phosphate synthase/phosphatase (T6PS/P). In another embodiment the genetic modification is to one or more nucleic acid sequence(s) or gene(s) encoding a trehalose phosphate hydrolase. In another embodiment the genetic modification is to one or more nucleic acid sequence(s) or gene(s) encoding a trehalase. In some embodiments the genetic modification can be to a promoter, terminator, binding site, or other regulatory sequence for a gene encoding the named biosynthetic pathway enzyme. The regulatory sequence may control transcription or translation of the encoded enzyme. In another embodiment the genetic modification is to any combination or sub-combination of the above one or more nucleic acid sequence(s) or gene(s), e.g. to T6PP and T6PS. But any combination or sub-combination of the recited nucleic acid sequences (or genes) can be genetically modified to achieve the desired effect. In a specific embodiment the genetic modification is an attenuation (e.g. to T6PS/P, or to T6PS and T6PP). In another embodiment the attenuation is a deletion.

[0050] In one embodiment the recombinant cells or organisms of the invention have a genetic modification to a gene or nucleic acid sequence encoding a trehalose-6-phosphate synthase/phosphatase (T6PS/P) in a trehalose biosynthetic pathway. For example, a modified organism of the invention (a Chlorophyte alga Parachlorella sp .) was found to have a nucleic acid sequence encoding a T6PS/P of SEQ ID NO: 2. This enzyme shows about 30% sequence identity to T6PP from Candida albicans. SEQ ID NO: 2 has a genetic modification (versus the unmodified “wild type” organism) at position 273 where a glutamic acid (E273) in the wild- type was changed to valine in the modified organism, which has increased biomass and/or lipid productivity. The E273 is conserved across species, but in some species the corresponding amino acid residue is an Asp. This residue can also be changed to Val in conserved sequences of other species or changed to another amino acid of similar chemical class in the corresponding position to achieve the high lipid phenotype exhibited by the mutant cells or organisms of the invention. For example, instead of a Val another nonpolar amino acid could be substituted such as, for example, any of Gly, Ala, Leu, He, Ser, Asn, Gin, Asp, or Met. Thus, in some embodiments the mutant cells or organisms of the invention have an E273V mutation, or a D273V mutation, or a E273X or D273X mutation, where X is any one of Gly, Ala, Leu, lie, Ser, Asn, Gin, Asp, or Met.

[0051] In various embodiments the encoded the trehalose biosynthetic pathway enzyme has at least 60% or at least 70% or at least 80% or at least 90% or at least 95% or at least 97%, or at least 98% amino acid sequence identity to SEQ ID NO: 2 (trehalose-6-phosphate synthase/phosphatase). In some embodiments the encoded trehalose biosynthetic pathway enzyme has at least 60% or at least 70% or at least 80% or at least 90% or at least 95% or at least 97% or at least 98% sequence identity to an amino acid sequence of at least 50 or at least 60 or at least 70 or at least 100 or at least 300 or at least 400 or at least 500 or at least 600 or at least 700 or at least 750 or at least 800 contiguous amino acids within any of SEQ ID NO: 2 or 4 or 5. In other embodiments the trehalose -6-phosphate synthase/phosphatase can be encoded by a nucleic acid sequence having at least 60% or at least 70% or at least 80% or at least 90% or at least 95% or at least 97% or at least 98% sequence identity to SEQ ID NO: 49.

[0052] In one embodiment the genetic modification inserts a stop codon into a coding sequence or regulatory sequence of one or more nucleic acid sequence(s) encoding a trehalose biosynthesis pathway enzyme to make a deletion or disruption of the gene. In one embodiment the genetic modification is a Glu723 to Val (E723V) mutation in the encoded polypeptide of SEQ ID NO: 2 (trehalose-6-phosphate synthase/phosphatase) or in a nucleic acid encoding a polypeptide having at least at least 60% or at least 70% or at least 80% or at least 90% or at least 95% or at least 98% sequence identity to SEQ ID NO: 2. Persons of ordinary skill will understand that a stop mutation or other mutation can be inserted at many other locations or loci within the nucleotide sequence, including in a promoter or other regulatory sequence of the gene, and achieve an attenuation of expression in the gene or in the activity of the encoded polypeptide. Such attenuation or other mutation can also cause a loss of function in the trehalose biosynthetic pathway enzyme and result in the effect of increase lipid productivity. RNA Binding Domain

[0053] RNA binding proteins (RBPs) are involved in RNA metabolism. The function of RBPs is varied and may include transient binding to RNA sequences to assist with splicing, regulation of alternative splicing, a component of hnRNP proteins (heterogeneous nuclear ribonucleoprotein), processing, transport, or localization. Most RBPs have multiple RNA binding domains that include different types of RNA binding motifs that recognize RNA sequences or targets. The RNA recognition motif known as RRM is the most abundant RNA binding domain. In the invention the RNA binding domain can be an RRM from any one or more of the organisms described herein. In one embodiment the RNA binding domain can be an RRM superfamily protein, for example RRM l . In other embodiments the RNA binding domain can be a protein from the PFAM 0076 family. SEQ ID NO: 1 is the polypeptide sequence of an RNA binding domain with two RNA Recognition Motif (RRM) domains in the N-terminal half of the coding sequence. Orthologs are found in many green algae (Chlorophytes) and plants. The recombinant algal cell of the invention can have a genetic modification to a nucleotide sequence encoding an RNA binding domain that has at least 50% sequence identity or at least 60% sequence identity at least 70% sequence identity or at least 75% or at least 80% or at least 85% or at least 90% or at least 95% or at least 98% amino acid sequence identity with SEQ ID NO: 1, or with the RRM domain of SEQ ID NO: 3, or to a sequence of at least 100 or at least 150 or at least 200 or at least 250 or at least 300 contiguous amino acids within SEQ ID NO: 1 or SEQ ID NO: 3. In various embodiments the RNA binding domain is encoded by a nucleotide sequence having at least 60% sequence identity at least 70% sequence identity or at least 75% or at least 80% or at least 85% or at least 90% or at least 95% or at least 98% amino acid sequence identity with SEQ ID NO: 50.

[0054] In some embodiments nucleotide orthologs can encode an RRM domain having at least 70% sequence identity or at least 75% or at least 80% or at least 85% or at least 90% or at least 95% or at least 98% (and, optionally, in any of the embodiments less than 100%) amino acid sequence identity with SEQ ID NO: 1 or SEQ ID NO: 3.

[0055] In some embodiments the genetic modification to the nucleic acid sequence is an attenuation or a deletion, but in other embodiments can be an insertion, a point mutation, a disruption, or any of the genetic modifications described herein. In one embodiment the genetic modification inserts a stop codon into a nucleic acid sequence or gene encoding an RNA binding domain described herein, or into a nucleic acid sequence or gene encoding a trehalose biosynthesis enzyme described herein, or into a nucleic acid sequence or gene encoding an SGI1 polypeptide. In one embodiment the genetic modification is a Lys36 to stop mutation (L36Stop or L36*) inserted into a nucleic acid sequence encoding SEQ ID NO: 1 (or, for example, an L15* inserted into a nucleic acid sequence encoding SEQ ID NO: 3), or into a nucleic acid sequence or gene having at least at least 60% or at least 65% or at least 70% or at least 75% or at least 80% or at least 85% or at least 90% or at least 95% or at least 97% or at least 98% (and, optionally, less than 100% in any embodiment) sequence identity to SEQ ID NOs: 1 or 3 or, similarly, to a sequence encoding at least 100 or 150 or 200 or 250 or 300 contiguous amino acids of SEQ ID NOs: 1 or 3. The stop codon or other modification can also be made at many other loci or locations within a nucleic acid sequence or gene or regulatory sequence encoding an RNA binding domain or trehalose biosynthetic pathway enzyme, for example at a promoter, terminator, or other regulatory sequence. Such modifications can achieve an attenuation of expression in the gene or in the activity of the encoded polypeptide. Analogous modifications can be made to the sequence(s) for similar effect. Such attenuation or other mutation can also cause a loss of function in the RNA binding domain, trehalose biosynthetic pathway enzyme, or SGI1 polypeptide, and result in the effect of increase lipid productivity.

SGI1 Polypeptide

[0056] As described herein, SGI1 or "Significant Growth Improvement 1" polypeptide is a polypeptide that includes a Response Regulator receiver or "RR" domain (pfam PF00072) and a Myb-like binding domain, referred to herein simply as a "myb" domain (pfam PF00249), where the RR domain is positioned N-terminal to the myb domain or the myb domain is C-terminal to the RR domain. The amino acid sequence of an SGI1 polypeptide that encompasses the RR domain and myb domain can include a stretch of amino acids that occurs between the RR and myb domains that may be poorly conserved or not conserved among SGI1 polypeptides. The amino acid sequence occurring between the RR domain and myb domain may be referred to herein as a linker between the two domains. The linker may be of any length, and in various examples may range in length from one to about 300 amino acids, from 10 to about 200 amino acids, or from 20 to about 150 amino acids in length. The linker region can optionally include a nuclear localization sequence (NLS).

[0057] An RR domain within an SGI1 protein can be characterized as pfam PF00072, or as a "signal receiver domain" or simply "receiver domain", and/or can be classified as cd00156 in the conserved domain database (CDD), as COG0784 in the Clusters of Orthologous Groups of proteins database, or as an Interpro "CheY-like superfamily" domain, IPR011006. The RR domain is found in bacterial two-component regulatory systems (like the bacterial chemotaxis two-component system that includes a polypeptide known as CheY), in which it receives a signal from a sensor partner. The RR domain of such systems is often found N-terminal to a DNA binding domain and can include a phosphoacceptor site. Alignment of the RR domains of algal SGI1 attenuation mutant strains can be shown. Sub-sequences of the RR domain from Parachlorella sp. WT-1185, Coccomyxa subellipsoidea , Ostreococcus lucimarinus , Chlamydomonas reinhardtii, Chromochloris zofmgiensis, Volvox carteri, Tetraselmis sp. 105, Oocystis sp. WT-4183, and Micromonas sp. RCC299 show substantial homology.

[0058] A myb domain within an SGI1 protein can be characterized, for example, as pfamPF00249: "Myb-like DNA-binding domain", and/or may be identified as conserved domain TIGR01557 "myb-like DNA-binding domain, SHAQKYF class", or as an Interpro Homeobox-like domain superfamily domain (IPR009057) and/or an Interpro Myb domain (IPROl 7930). Alignment and substantial homology was also shown of the Myb domains of algal SGI1-KO strains. Shown are sub-sequences of the Myb domains from Parachlorella sp. WT-1185, Coccomyxa subellipsoidea , Ostreococcus lucimarinus , Chlamydomonas reinhardtii , Chromochloris zofingiensis, Volvox carteri, Tetraselmis sp . 105, Oocystis sp. WT- 4183, and Micromonas sp. RCC299.

[0059] In addition to having an RR domain N-terminal to a myb domain, an SGI1 protein as provided herein can have a score of 300 or higher, 320 or higher, 340 or higher, 350 or higher, 360 or higher, or 370 or higher with an e-value of less than about le-10, le-50, le-70, or le-100, when scanned with a Hidden Markov Model (HMM) designed to score proteins on the basis of how well a protein's amino acid sequence matches the conserved amino acids of a region of SGI1 homologs in algae. The region of SGI1 polypeptides used to develop the HMM is the amino acid sequence that includes (proceeding in the N-terminal to C-terminal direction) the RR domain, the linker, and the myb domain. In a HMM, highly conserved amino acid positions are weighted more heavily than poorly conserved amino acid positions within a compared region of the polypeptides to arrive at the score. Polypeptides having scores of at least about 300, or of 350 or greater, such as for example 370 or greater, when scanned with an HMM model based on protein sequences of algal SGI1 polypeptides that include a single continuous sequence that includes the RR domain, linker, and myb domain developed using include, without limitation, polypeptides of the algal and plant species Parachlorella sp. 1185 (SEQ ID NO: 8), Coccomyxa subellipsoidea (SEQ ID NO: 9), Ostreococcus lucimarinus (SEQ ID NO: 10), Chlamydomonas reinhardtii (SEQ ID NO: 11), Chromochloris zofmgiensis (SEQ ID NO: 12), Volvox carteri (SEQ ID NO: 13), Tetraselmis sp. 105 (SEQ ID NOs: 14-16, Oocystis sp. (SEQ ID NO: 17), Micromonas sp. RCC299 (SEQ ID NO: 18), and Micromonas pusilla (SEQ ID NO: 19), Sphagnumfallax (SEQ ID NO:20), and Physcomitrella patens (SEQ ID NO:21). Additional SGI1 orthologs from additional algae species are identifiable by persons of ordinary skill in the art.

[0060] The SGI1 polypeptide encoded by a nucleic acid comprised by the recombinant algal or plant cells of the invention can have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (and, optionally, in any embodiment less than 100%) amino acid sequence identity to any SGI1 polypeptide sequence of SEQ ID NOs: 6-21, or to fragments of any of them comprising a consecutive sequence of at least 100, or at least 125, or at least 150, or 200 or more amino acid residues of the entire protein where the polypeptide has an RR domain and a myb domain, and the RR domain can be N-terminal to the myb domain, where the SGI1 polypeptide is a naturally occurring polypeptide or a variant thereof. In various embodiments, the SGI1 polypeptide is from a plant or algal species, i.e., is a naturally-occurring polypeptide of a plant or algal species. A gene or nucleotide sequence encoding an SGI1 polypeptide as provided herein, for example a gene that is disrupted or whose expression is attenuated in a mutant as provided herein, can be a naturally-occurring gene of a plant or algal species that encodes a polypeptide as disclosed herein.

[0061] In various embodiments the encoded SGI1 polypeptide can have a (Myb domain) amino acid sub-sequence having at least 75% or at least 80% or at least 85% or at least 90% or at least 95% or at least 98% (and, optionally, in any embodiment less than 100%) sequence identity to a Myb domain sequence of any of SEQ ID NO: 22-30, or to a consecutive sequence of at least 25, or at least 30, or at least 50 or at least 75 amino acid residues of the entire sequence. In various embodiments any of these myb domains can be present in an SGI1 polypeptide with any of the RR domains described herein (e.g. SEQ ID NO: 31-48).

[0062] An SGI1 gene that encodes a polypeptide having the sequence of a naturally- occurring algal SGI polypeptide can be a gene having a naturally-occurring gene sequence, or can have a sequence that varies from the sequence of a naturally-occurring gene. In various embodiments, an SGI1 gene that is attenuated, mutated, or disrupted in a mutant photosynthetic organism as disclosed herein can be a gene that is identified through homology searching, for example, using one or more sequences disclosed herein as queries, and/or by HMM scanning, where the HMM is built from amino acid sequences, for example upon multiple alignment of at least six SGI1 polypeptides, where the amino acid sequences include an RR domain and a myb domain, where the RR domain is N-terminal to the myb domain, and where there is a linker sequence between the RR and myb domains that does not belong to either domain. [0063] In some embodiments, an SGI1 polypeptide can be the sequence of an algal or plant SGI1 polypeptide, or is a variant of a naturally-occurring algal or plant SGI1 polypeptide, and can contain a Response Regulator receiver domain as a sub-sequence, for example a sub sequence of any of SEQ ID NO: 6-21, which can be a consecutive sequence of at least 25, or at least 30, or at least 50 or at least 75 amino acid residues of the entire sequence. The Response Regulator receive domain can contain an amino acid sub-sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (and, optionally, in any embodiment less than 100%) sequence identity to any one of the Response Regulator receiver domains of SEQ ID NO: 31-48, or to a consecutive sequence of at least 25, or at least 30, or at least 50 or at least 75 amino acid residues of the entire sequence.

[0064] Persons of ordinary skill know how to calculate the percent of “sequence identity” between two sequences. In one embodiment the percent of sequence identity can be determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx (Altschul (1997), Nucleic Acids Res. 25, 3389-3402, and Karlin (1990), Proc. Natl. Acad. Sci. USA 87, 2264-2268). In one embodiment the search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix, and filter (low complexity) can be at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx can be the BLOSUM62 matrix (Henikoff (1992), Proc. Natl. Acad. Sci. USA 89, 10915-10919). For blastn the scoring matrix can be set by the ratios of M (i.e., the reward score for a pair of matching residues) to N (i.e., the penalty score for mismatching residues), wherein the default values for Mand N can be +5 and -4, respectively. Four blastn parameters can be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=l (generates word hits at every winkth position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings for comparison of amino acid sequences can be: Q=9; R=2; wink=l; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, can use DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty), and the equivalent settings in protein comparisons can be GAP=8 and LEN=2.

Recombinant Alga

[0065] The recombinant mutant algae of the invention demonstrate a significant increase in the production of lipid in the organism, which can be measured (for example) using fatty acid methyl esters (FAME) analysis. The increase in lipid production can be measured as an increase in total FAME produced by the organisms. The recombinant cells of the invention having a genetic modification to a nucleic acid sequence or gene encoding a trehalose biosynthesis pathway enzyme disclosed herein and/or a genetic modification to a nucleic acid sequence encoding an RNA binding domain disclosed herein and, optionally for any of them, a genetic modification to a nucleic acid sequence encoding an SGI1 polypeptide disclosed herein, can exhibit at least 50% or at least 60% or at least 70% or at least 80% or at least 90% or at least 100% greater lipid productivity compared to a corresponding control alga. In other embodiments the increase in lipid productivity can be 15-35% or 15-40% or 25-45% or 15- 50% or 25-70% or 25-90% or 25-100% or 25-150% or 25-200%. In one embodiment lipid productivity is measured using total fatty acid methyl ester assay (FAME) known to persons of ordinary skill in the art.

[0066] In another embodiment the recombinant cells of the invention having the genetic modification to one or more trehalose biosynthesis pathway enzyme(s) and/or a genetic modification to one or more RNA binding domain(s) and, optionally for any of them, a genetic modification to one or more nucleic acid sequence(s) encoding SGI1 polypeptide, exhibit at least 50% or at least 60% or at least 70% or at least 80% or at least 90% or at least 100% or at least 150% or at least 200% greater biomass productivity versus a control alga. In other embodiments the increase in biomass productivity can be 15-35% or 15-40% or 25-45% or 15- 50% or 25-70% or 50-100% or 50-200%. In one embodiment the biomass productivity can be measured as total organic carbon (TOC) using assays known to persons of ordinary skill in the art.

[0067] The recombinant cells or organisms of the invention can have the disclosed higher amounts of lipid productivity and/or the higher disclosed amounts of biomass productivity. Increased Lipid Productivity

[0068] Any of the recombinant algal cells disclosed herein can exhibit increased lipid productivity. For example, recombinant algal cells having a genetic modification to one or more nucleic acid sequence(s) encoding a trehalose biosynthetic enzyme (e.g. trehalose-e- phosphate synthase/phosphatase) and/or to one or more nucleic acid sequence(s) encoding an RNA binding domain and, optionally with either or both of them, a genetic modification to one or more nucleic acid sequence(s) encoding SGI1 polypeptide, exhibit higher lipid productivity. [0069] In any embodiment lipid productivity can be measured using the fatty acid methyl ester (FAME) profile, which is known to persons of ordinary skill in the art. In various embodiments any of the recombinant algal cells or organisms of the invention can produce at least 20% more or at least 25% more or at least 30% more or at least 35% more, or at least 50% more or at least 60% more or at least 70% more or at least 80% more or at least 90% more or at least 100% more or at least 125% more or at least 150% more or at least 200% more lipid product than a corresponding (control) cell or organism. In one embodiment the lipid productivity can be measured using the FAME profile of the respective cells or organisms. [0070] An increase in lipid production or lipid productivity can also be measured in grams per square meter per day of the surface of a cultivation vessel (e.g. a flask, photobioreactor, cultivation pond). In various embodiments the recombinant alga of the invention produce at least 3 or at least 4 or at least 5 or at least 6 or at least 7 grams per square meter per day of lipid, which can be measured by the FAME profile. In any of the embodiments the high lipid and/or high biomass productivity phenotype can be obtained under nitrogen deplete conditions, which can be with semi-continuous dilutions (e.g. dilution by about 30% or by about 40% or by about 50%, once per day, and replacing with fresh medium). In one embodiment the lipid product is a fatty acid and/or derivative of a fatty acid. In one embodiment the fatty acids and/or derivatives of fatty acid comprise one or more species of molecules having a carbon chain between C8-C18 or C8-C20 or C8-C22 or C8-C24.

[0071] In any of the embodiments the genetic modification to a gene or nucleic acid sequence encoding a RBD domain described herein and/or a gene or nucleic acid sequence encoding a trehalose biosynthetic pathway enzyme described herein, and optionally with either or both of them, a genetic modification to a nucleic acid sequence encoding an SGI1 polypeptide described herein, can result in an attenuation of expression of the respective genes. The genetic modification of any one or more of these genes or nucleic acid sequences can be a knockout, a targeted mutation and gene replacement, a gene replacement, a promoter replacement, a deletion, an insertion, a substitution, a functional deletion, a disruption in a gene or in its regulatory sequence, as well as the introduction of transgenes into the organism. Biomass Productivity

[0072] The recombinant algal cells of the invention can also have higher biomass productivity than a corresponding organism not having a genetic modification to the gene or nucleic acid sequence encoding one or more trehalose biosynthetic pathway enzyme(s) described herein and/or to one or more gene(s) or nucleic acid sequence(s) encoding an RBD domain described herein and, optionally with either or both of them, a genetic modification to a gene or nucleic acid sequence encoding one or more SGI1 polypeptide(s) described herein. Biomass can be measured using the total organic carbon (TOC) analysis, known to persons of ordinary skill in the art. The recombinant cells can have at least 20% higher or at least 25% higher or at least 30% higher or at least 35% higher, or at least 50% higher or at least 60% higher or at least 70% higher or at least 80% higher or at least 90% higher or at least 100% higher or at least 125% higher or at least 150% higher or at least 200% higher biomass productivity than a corresponding (control) cell or organism, which can be measured by total organic carbon analysis. Biomass productivity can be measured as mg/ml of culture per time period (e.g. 1 day or 2 days or 3 days or 4 days or 5 days).

[0073] In any of the embodiments the recombinant alga can have the amounts of higher biomass productivity and/or higher lipid productivity stated herein under nitrogen deplete conditions. Thus, in one embodiment the recombinant alga of the invention can have higher total organic carbon production than a corresponding (control) cell or organism, which higher amount can be produced under nitrogen deplete or low nitrogen conditions. In one embodiment biomass productivity can be evaluated by measuring an increase in the total organic carbon of the cells.

Methods of Producing Lipid

[0074] The invention also provides methods for producing a composition containing lipids. The methods involve subjecting a culture of algal organisms described herein to at least one treatment of uv radiation (or gamma radiation, or both) to produce a recombinant algal organism described herein, cultivating the recombinant algal organisms in a suitable medium (such as any described herein), and thereby producing a composition containing lipids. Optionally the lipids can be isolated from the recombinant algal organisms. The recombinant alga can be cultivated in any suitable media, such as any of those described herein. The uv treatment can involve, for example, subjecting the culture to uv light (or gamma radiation, or both) for a suitable period of time or under a suitable uv regimen. The recombinant alga can be cultivated for at least 2 days or at least 3 days, or at least 4 days, or at least 5 days, or at least 6 days, or at least 10 days, or at least 20 days, or from 2-10 days, or from 2-20 days or from 2- 25 days.

[0075] Any of the recombinant cells or organisms of the invention can be cultivated in batch, semi-continuous, or continuous culture. In some embodiments the culture medium can be nutrient replete, or nitrogen deplete (-N). In some embodiment the culturing is under photoautotrophic conditions, and inorganic carbon (e.g., carbon dioxide or carbonate) can be the sole or substantially the sole carbon source in the culture medium. Nitrogen deplete conditions can be achieved by utilizing a culture medium that has no significant source of nitrogen available for cell growth. In various embodiments nitrogen deplete conditions can involve culturing in a buffer having less than 0.5 mM of nitrogen in any available form external to the cell or organism. In some embodiments the cells can be cultured in 0.5 mM or less of KN03 or urea as a nitrogen source.

[0076] The invention also provides methods of producing a biofuel involving cultivating a recombinant algal organism described herein. The methods can also include a step of harvesting a biofuel from a recombinant algal organism of the invention. The recombinant organism can be cultivated in any growth medium, such as any described herein. In one embodiment the recombinant organism is cultivated in a nitrogen deplete medium. In various embodiments the cultivating can occur for a period of at least 3 days or at least 5 days or at least 7 days or at least 15 days or at least 20 days.

FAME and TOC Analysis Methods

[0077] The lipid productivity of the cells or organisms can be measured by any method accepted in the art, for example as an increase or decrease in fatty acid methyl esters (FAME) comprised in the cell, i.e. analysis of the cell or organism’s FAME profile. In some embodiments any of the recombinant algal cells or organisms of the invention can have higher biomass productivity versus corresponding control cells or organisms. In some embodiments any of the recombinant algal cells or organisms of the invention can have both higher lipid productivity and higher biomass productivity compared to a corresponding control cell or organism. Biomass productivity can be measured by any methods accepted in the art, for example by measuring the total organic carbon (TOC) content of a cell. Embodiments of both methods are provided in the Examples.

[0078] "FAME lipids" or "FAME" refers to lipids having acyl moieties that can be derivatized to fatty acid methyl esters, such as, for example, monoacylglycerides, diacylglycerides, triacylglycerides, wax esters, and membrane lipids such as phospholipids, galactolipids, etc. In some embodiments lipid productivity is assessed as FAME productivity in milligrams per liter (mg/L), and for algae, may be reported as grams per square meter per day (g/m2/day). In semi-continuous assays, mg/L values are converted to g/m2/day by taking into account the area of incident irradiance (the SCPA flask rack aperture of 1 ½ inches x 33/8", or 0.003145 m2) and the volume of the culture (550 ml). To obtain productivity values in g/m2/day, mg/L values are multiplied by the daily dilution rate (30%) and a conversion factor of 0.175. Where lipid or subcategories thereof (for example, TAG or FAME) are referred to as a percentage, the percentage is a weight percent unless indicated otherwise. The term "fatty acid product" includes free fatty acids, mono-di, or tri-glycerides, fatty aldehydes, fatty alcohols, fatty acid esters (including, but not limited to, wax esters); and hydrocarbons, including, but not limited to, alkanes and alkenes).

EXAMPLES

EXAMPLE 1 - PRODUCTION OF SGI1 MUTANTS

[0079] The production of algal strains containing a genetic modification in a nucleic acid sequence encoding an SGI1 polypeptide is known in the art and is detailed in US 2018/0186842, published July 5, 2018, and which is hereby incorporated by reference in its entirety, including all tables, figures, and claims.

[0080] Briefly, wild-type Parachlorella sp. (a Chlorophyte, or green algae species) obtained from marine environments were mutagenized with uv radiation in a STRATALINKER ^® 2400 uv crosslinker (Agilent Technologies, Santa Clara, CA) and selected based on low chlorophyll fluorescence after low light acclimation.

[0081] The cells were grown to mid-log phase and then diluted to lxlO ⁶ (le6) cells/mL with a nutrient replete growth medium. The cell suspensions were transferred to a Petri dish and placed within a STRATALINKER® 2400 UV crosslinker (Agilent Technologies, Santa Clara, CA) with the plate lid removed. UV irradiation was carried out with 10,000, 25,000, and 50,000 pj/cm2. After irradiation, cell suspensions were pipetted into a shake flask wrapped in foil to prevent light exposure for twenty-four hours during recovery. Following mutagenesis and recovery cells from pale colored colonies were selected and allowed to grow from between one and five days in low (100 pmol photons m-2 sec-1) light, after which they were sorted by flow cytometry to select cells having low chlorophyll fluorescence.

[0082] Further primary screening of antenna-reduced lines isolated through flow cytometry was conducted through the selection of pale green or yellow colonies visually after sorted cells were plated. In order to screen putative antenna-reduced lines from other reduced pigment mutants and false positives, selected colonies were subjected to a medium-throughput secondary cultivation screen to acclimate the isolates to low light conditions prior to photo- physiological measurements. Chlorophyll fluorescence was monitored during low light acclimation to select colonies that retained the reduced chlorophyll fluorescence characteristic of the high light acclimated state. Clones that were selected demonstrated only small increases in chlorophyll (relative to wild type cells) when transferred from high to low light.

[0083] Semi-continuous culture assays in constant high light (approximately 1,700 pmol photons m-2 sec-1) using 165 ml cultures in 75 cm2 tissue culture flasks were performed to identify strains having increased productivity (increased rate of biomass production, measured as TOC accumulation) with respect to the wild type progenitor. Two 75 cm2 flasks were inoculated with seed culture of a given mutant strain with C02-enriched air (1 % C02) bubbled through the cultures. Samples for TOC analysis were taken from the culture removed for the dilution. Isolates were identified having increased productivity.

[0084] Genome sequencing and genotyping of resultant strains revealed mutations including distinct SNPs. The effect of higher biomass productivity was found to be related to an SNP in the sequence of SGI1 polypeptide at amino acid 250, which was changed from Leu to Pro (i.e. a Leu250Pro SNP). The gene encoding SGI1 polypeptide in Parachlorella sp. has the nucleotide sequence of SEQ ID NO: 6, and the coding sequence of SEQ ID NO: 7, which encodes the amino acid sequence of SEQ ID NO: 8. The SNP was found to result in a Leu250Pro mutation in SGI1 polypeptide. This mutation was recapitulated in a wild-type Cas9 editor strain of Parachlorella sp. to produce “SGI1 mutants,” and these cells were then used in subsequent procedures.

EXAMPLE 2 - MUTAGENESIS

[0085] The SGI1 mutants from Example 1 were irradiated with uv light in a STRATALINKER ^® 2400 uv crosslinker (Agilent Technologies ^® , Santa Clara, CA). Irradiation was done in four dosages with duplicates per dosage. Cells were diluted to a concentration of 5xl0 ⁶ (5e6) cells/ml and irradiated on agar plates with approximately 5xl0 ⁷ (5e7) cells total per petri dish. Irradiation dosages included 16 seconds at 27,000 uJ/cm , 12 9 seconds at 20,000 x uJ/cm ,8 seconds at 13,000 uJ/cm , and 6 seconds at 10,000 uJ/cm .

EXAMPLE 3 - GROWTH AND BODIPY STAINING [0086] Mutagenized cells were then grown to a suitable concentration as measured by OD730 of 3.0 in flasks containing PM074 media. Cells were then transferred to media containing PM123 media (aquarium salts, PROLINE A ^® , and PROLINE B ^® (Pentair Aquatic Eco-Systems ^® , Inc.)) and a final OD730 of 0.1 (PROLINE A ^® and PROLINE B ^® together include 8.8 mM NaN03, 0.361mM NaH2P04.H20, lOx F/2 Trace metals, and lOx F/2 Vitamins (Guillard (1975) “Culture of phytoplankton for feeding marine invertebrates,” eds. Smith, W.L. and Chanley, M.H., Plenum Presse, New York, pp. 26-60). After growing to suitable concentration (OD730 of 2.8) cells were spun down in a centrifuge and re-suspended in flasks containing nitrogen-free PM67 media (aquarium salts, K2HP04, vitamin mix, chelated trace metal mix). Cells were placed in a glass tank flask and a final concentration of cells of OD730 of 1.4 was reached and cells were placed under a constant stream of 1% C02 in air.

[0087] After 48 hours of batch growth in nitrogen deplete media (i.e. the culture medium had no nitrogen source) an aliquot of cells was removed and subjected to staining with the lipid-specific dye BODIPY (boron-dipyrromethene). Mutant cells with the highest level of BODIPY staining were enriched by fluorescence activated cell sorting (FACS). Enriched cell populations were grown and re-inoculated and allowed to grow as above, and again subjected BODIPY staining and FACS at 48 h under nitrogen deplete (-N) batch growth. This iterative process was repeated for a total of five rounds of sorting, with the final sort resulting in single cell isolates.

EXAMPLE 4 - FAME AND TOC ANALYSIS [0088] Once rendered axenic from bacterial contamination by treatment of cultures with streptomycin at 0.6 mg/ml, isolates having the SGI1 mutation plus the RNA binding domain (RBD) and trehalose-6-phosphate synthase/phosphatase (Tre6P) attenuations were cultivated under nitrogen-deplete growth conditions and compared to the parental SGI1-KO only mutant strain for nitrogen-deplete batch lipid and biomass productivity. The FAME and TOC measurements show the amount of fixed carbon that is partitioned to lipids and nitrogen-deplete lipid productivity. Figure la shows that the isolates exhibited an increase in FAME/TOC ratio (an indicator of how much fixed carbon is partitioned to lipids) compared to the SGI1-KO only mutants, and Figure lb shows higher TOC productivity. Thus, mutants having the SGIl+RBD+Tre6P attenuations were isolated and had improved lipid productivity versus mutants having the SGI1-KO alone.

[0089] Total organic carbon (TOC) of the algal culture samples was determined by diluting 2 mL of cell culture to a total volume of 20 mL with DI water. Three injections per measurement were injected into a TOC high sensitivity analyzer for determination of Total Carbon (TC) and Total Inorganic Carbon (TIC). The combustion furnace was set to 720°C, and TOC was determined by subtracting TIC from TC. The 4-point calibration range was from 2 ppm to 200 ppm corresponding to 20-2000 ppm for non-diluted cultures with a correlation coefficient of r ² (r squared) greater than 0.999.

[0090] To determine lipid content, FAME analysis was performed on 2 mL samples that were dried using an evaporator. To the dried pellets the following was added: 500 pL of 500 mM KOH in methanol, 200 pL of tetrahydrofuran containing 0.05% butylated hydroxyl toluene, 40 pL of a 2 mg/ml Cl 1:0 free fatty acid/C13:0 triglyceride/C23:0 fatty acid methyl ester internal standard mix and 500 pL of glass beads (425-600 um diameter). The vials were capped with open top PTFE septa-lined caps and placed in a tissue homogenizer at 1.65 krpm for 7.5 minutes. The samples were then heated at 80°C for five minutes and allowed to cool. For derivatization, 500 pL of 10% boron trifluoride in methanol was added to the samples prior to heating at 80°C for 30 minutes. The tubes were allowed to cool prior to adding 2 mL of heptane and 500 pL of 5 M NaCl. The samples were then vortexed for five minutes at 2 krpm and finally centrifuged for three minutes at 1 krpm. The heptane layer was sampled using an autosampler. Quantitation used the 80 pg of C23 :0 FAME internal standard.

EXAMPLE 5 - GENOTYPING OF MUTANTS [0091] Genomic DNA was isolated from these mutants and from the SGI1 only mutant parental strain (STR0012) and the wild-type corresponding control strain (STR0010). Isolated gDNA was sequenced using Next Generation sequencing on an Illumina ^® instrument (Illumina, Inc., San Diego, CA). Sequence reads were processed, mapped to the wild type reference genome and analyzed by a small variants caller algorithm (derived from the FreeBayes polymorphism detection software, which is a Bayesian genetic variant detector designed to find small polymorphisms, specifically SNPs, indels (insertions and deletions), MNPs (multi nucleotide polymorphisms), and complex events (composite insertion and substitution events) smaller than the length of a short-read sequencing alignment. Analysis of small nucleotide polymorphisms (SNPs) and small insertions/deletions (InDels) revealed the sequenced strains to be genetic siblings of each other having a core set of 28 polymorphisms shared across the strains.

[0092] The SNPs shown in Table 1 revealed the candidate genes where the underlying causative mutations causing the high lipid phenotype might occur. Fifteen SNPs were either intergenic or present in introns of a gene; assessment of transcriptomics and RNA sequence data from the new mutants indicated that these SNPs had no impact on neighboring gene expression or intron splicing. [0093] But thirteen of the 28 SNPs were prioritized for genetic recapitulation based on the deduced change in coding sequence of the encoded gene. One of the 13 sibling high lipid mutants, named Strain 600 (STR0600), was selected for all further experiments. The 13 mutants were identified as noted in Table 1.

Table 1

EXAMPLE 6 - GENETIC RECAPITULATION

[0094] To determine the mutation(s) that are the cause of the high lipid phenotype, knockouts, and/or exact recapitulation of SNPs observed in STR0600 were re-created in a markerless Cas9/Cre expression strain containing a SGI1 knockout (SGI1-KO). In addition, a variant of STR00600 in which Cas9/Cre expression cassettes were integrated in a markerless fashion was generated in order to examine the effect of reverting SNPs back to wild type. Thus individual SNPs could be evaluated to determine which were necessary to produce the high lipid phenotype, and whether the phenotype might have a complex genetic underpinning where one SNP is not sufficient to recapitulate the phenotype.

[0095] All strains generated were tested for the high lipid and/or high biomass productivity phenotype under nitrogen deplete (-N) batch conditions in a simplified assay conducted in T25 flasks containing PM153 buffer for an OD730 of 0.1. PM153 is a nutrient replete medium that is based on PM074 but includes urea instead of nitrate as the nitrogen source. It is made by adding 1.3 ml Proline ^® F/2 Algae Feed Part A (Pentair Aquatic Eco-Systems) and 1.3 ml 'Solution C to a final volume of 1 liter of a solution of aquarium salts (17.5 g/L), and then adding 4 ml if 1.1 M filter-sterilized urea. Solution C is 38.75 g/L NaH2P04 H20, 758 mg/L thiamine HC1, 3.88 mg/L vitamin B12, and 3.84 mg/L biotin.

[0096] PM074 is a nutrient replete medium. While any suitable algal growth medium can be employed in the invention, PM074 is made by adding 1.3 ml Proline ^® F/2 Algae Feed Part A (Pentair Aquatic Eco-Systems, Inc., Apopka, FL) and 1.3 ml Proline ^® F/2 Algae Feed Part B to a final volume of 1 liter of a solution of Instant Ocean salts (35 g/L) (Pentair Aquatic Eco- Systems Inc., Apopka, FL). Proline A ^® and Proline B ^® together include 8.8 mM NaN03, 0.361mM NaH2P04.H20, lOx F/2 Trace metals, and lOx F/2 Vitamins (Guillard (1975) Culture of phytoplankton for feeding marine invertebrates in "Culture of Marine Invertebrate Animals." (eds: Smith W.L. and Chanley M.H.) Plenum Press, New York, USA. pp 26-60). [0097] For biomass and lipid productivities, strains were pre-acclimated in a 14: 10 diel 1% C02 incubator and scaled to 1000ml in PM153 media. Cultures were normalized to about 350mg/l TOC, which is 60% of the empirically determined steady state standing biomass density for a daily 40% dilution rate. The total culture volume was 420ml in a 500ml square polycarbonate bottle. Flasks were kept at 30 °C using a water bath, stirred via magnetic bar and 1% C02 bubbled at 300ml/min. Light was supplied by LED panels through a 0.0875m2 aperture and programmed to a 14:10 diel cycle. For nitrogen replete biomass productivity measurements, samples were taken for OD730, Flow Cytometry, FAME and TOC analysis at dusk and the cultures diluted back 40% with PM153 in a semi-continuous manner for 8-9 days. Following the nitrogen replete semi-continuous mode, the flask was removed at dusk, pelleted and the supernatant discarded. The strains were resuspended in PM152 (nitrogen-deplete) media and normalized to about 250mg/l TOC as empirically determined to give maximal lipid productivity. The cultures were placed back into new 500ml bottles at 420ml volume as above. The cultures were grown in batch mode to test lipid productivity during nitrogen deplete induction with sampling again at dusk. [0098] Two mutations were identified as giving rise to the high lipid phenotype. The mutations identified were a Glu723 Val (E723 V) mutation in the encoded Tre6P enzyme (SEQ ID NO: 2), and a Lys36Stop (Lys36*) mutation in the encoded RBD (SEQ ID NO: 1). It was observed that 1) introducing the Tre6P SNP into a SGI1-KO mutant to produce a mutant having the SGIl-KO+Tre6P attenuation provided a strain with increased lipid productivity, as shown in Figure 2a; 2) repair of the RBD attenuation to wild-type in Strain 600 (SGIl+RBD+Tre6P) to produce a strain having the SGIl+Tre6P attenuation, resulted in a strain having a decreased lipid productivity (Figure 2b); 3) introducing the RBD attenuation into the SGIl-only mutant strain resulted in increased lipid productivity under nitrogen deplete batch growth, as shown in Figure 3a; 4) Tre6P repair in the SGIl+Tre6P+RBD (STR0600) strain resulted in a reduced - N batch lipid productivity, as shown in Figure 3b, but was still higher than the wild type strain (STR0010) and reached almost as high as the STR0600 having all three modifications; 5) repair of the SGI1 mutation in STR00600 resulted in a reduced -N (nitrogen deplete) batch lipid productivity and TOC productivity, as shown in Figure 5a and 5b. Figure 2c also shows significantly higher FAME productivity for the SGIl+Tre6P+RBD mutant strain (STR0600) under batch conditions.

[0099] As noted, the strain designated STR0600 has all three genetic modifications, 1) the SGI1 mutation, 2) the RBD mutation, and 3) Tre6P mutations. Figures 4a-4b show that the SGIl-only mutant (STR012) exhibited an approximately 30% higher FAME production and TOC production versus the wild-type. Figures 4a-4b also show three independent lines that were generated having the SGI1 mutation as well as the RBD and Tre6P attenuations - all three lines showed a lipid productivity and TOC equivalent to STR0600. Figures 5a and 5b show two strains (680, 681) having only the RBD and Tre6P mutations, and one having only the SGI1 and Tre6P mutations - these strains showed greater FAME accumulation at Day 2 (55%, 59%, and 49% for FAME, respectively) than wild-type (STR010). The strains also showed 19%, 15% higher TOC accumulation than wild-type for 2-day TOC accumulation). RBD repair resulted in a drop in lipid productivity to a level below the STR0600 and similar to that of the 680 and 681 (RBD+Tre6p) strains.

[0100] Therefore, it was shown that the RBD and Tre6P mutations can be “stacked” in an SGI1 mutation strain to recapitulate the high lipid phenotype of STR0600, and the mutations giving rise to the phenotype resolved. EXAMPLE 7 - MUTATION IDENTIFICATION

[0101] The genomes of the organisms were sequenced and amino acid sequences of the encoded RBD and Tre6P polypeptides were determined to be SEQ ID NO: 1 and SEQ ID NO: 2, respectively, from the Parachlorella sp. Analyses of functional annotation and orthologs present in other organisms revealed that the gene encoding the RNA binding domain protein (SEQ ID NO: 1) has two RNA Recognition Motif (RRM) domains in the N-terminal half of the coding sequence. BLAST searching revealed that orthologs are broadly distributed in green algae with about 50% sequence identity and about 75% positive amino acid identity within amino acid chemical classes (aliphatic, hydroxyl or sulfur-containing, cyclic, aromatic, basic, and acidic and their amide) with the RRM domain observed in maize. The Musashi-like proteins of this class are well characterized RBD proteins (J Cell Sci. 2002 Apr 1 ; 115 (Pt 7): 1355-9), and the function of this class of proteins is believed to be the targeted regulation of translation of mRNAs, and the encoded RNA binding domains in the present case may therefore have similar or the same function.

[0102] SEQ ID NO: 2 is the sequence of a trehalose-6-phosphate synthase/phosphatase from Parachlorella sp. that could catalyze reactions analogous to both the Tspl and Tsp2 reactions of Candida albicans , presented as an example in Figure 6. The Glu723 was found to be well conserved in homologues as Glu or, in some cases, aspartic acid. Nevertheless, in the recombinant alga of the invention it was found to have mutated to valine and was found to be an E723 V mutation.

[0103] Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.